LABOPHARM TO HOST CONFERENCE CALL THURSDAY, November 11, 2010 AT 8:30 A.M. (ET)

Oct 28, 2010, 07:00 ET from Labopharm Inc.

- Management to discuss third quarter 2010 financial results -

LAVAL, QC, Oct. 28 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Thursday, November 11, 2010 at 8:30 a.m. (ET) to discuss its third quarter 2010 financial results. Labopharm will report its third quarter 2010 financial results via news release at approximately 7:00 a.m. (ET) the same day.

To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  Please connect approximately 15 minutes prior to the beginning of the call to ensure participation.  The conference call will be archived for replay until Thursday, November 18, 2010 at midnight.  To access the archived conference call, dial 416-849-0833 or 1-800-642-1687 and enter the reservation number 20893179.

A live audio webcast of the conference call will be available at href="http://www.labopharm.com/">www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.  The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Headquartered in Laval, Canada with U.S. offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 19 countries around the world, including the U.S., Canada, major European markets, South Korea and Australia.  Its second product, OLEPTRO™, a novel formulation of trazodone for the treatment of major depressive disorder in adults is now available in the U.S. and is under regulatory review in Canada. Its third product, a twice-daily formulation of tramadol-acetaminophen is approved in multiple countries in Europe. The Company also has a pipeline of follow-on products in both pre-clinical and clinical development.

SOURCE Labopharm Inc.